Cas:17274-68-9 5-Bromo-3-[2-(1-pyrrolidinyl)ethyl]-1H-indole manufacturer & supplier

Chemical Name:5-Bromo-3-[2-(1-pyrrolidinyl)ethyl]-1H-indole

CAS.NO:17274-68-9

Synonyms:5-Bromo-3-[2-(1-pyrrolidinyl)ethyl]-1H-indole;1H-Indole, 5-bromo-3-[2-(1-pyrrolidinyl)ethyl]-;5-Bromo-3-[2-(pyrrolidin-1-yl)ethyl]-1H-indole

Molecular Formula:C₁₄H₁₇BrN₂

Molecular Weight:293.202

HS Code:2933990090

Physical and Chemical Properties:

Melting point:N/A

Boiling point:419.5±30.0 °C at 760 mmHg

Density:1.4±0.1 g/cm3

Index of Refraction:1.654

PSA:19.03000

Exact Mass:292.057495

LogP:3.49

Material Safety Information (Applicable for Hazard Chemicals)

RIDADR:

Packing Group:

Contact us for information like 5-Bromo-3-[2-(1-pyrrolidinyl)ethyl]-1H-indole chemical properties,Structure,melting point,boiling point,density,molecular formula,molecular weight,5-Bromo-3-[2-(pyrrolidin-1-yl)ethyl]-1H-indole physical properties,toxicity information,customs codes,safety, risk, hazard and MSDS, CAS,cas number,1H-Indole, 5-bromo-3-[2-(1-pyrrolidinyl)ethyl]- Use and application,5-Bromo-3-[2-(1-pyrrolidinyl)ethyl]-1H-indole technical grade,usp/ep/jp grade.

Related News: The three products for which it received the PLI approvals are betamethasone with a production capacity of 12 MT at an investment of Rs 31.43 crore, dexamethasone of 10 MT with an investment of Rs. 26.19 crore and prednisolone of 15 MT at Rs 39. 29 crore. This takes the total investment to Rs 96.91 core. 3-(6,7-dihydroxy-4,5-dimethyl-2-oxoquinazolin-1(2H)-yl)propanoic acid hydrobromide manufacturers The three products for which it received the PLI approvals are betamethasone with a production capacity of 12 MT at an investment of Rs 31.43 crore, dexamethasone of 10 MT with an investment of Rs. 26.19 crore and prednisolone of 15 MT at Rs 39. 29 crore. This takes the total investment to Rs 96.91 core. Benzeneethanamine, α-methyl- suppliers The Institute for Clinical and Economic Review (ICER) on Friday released its report examining the cost-effectiveness of Soliris, also known as eculizumab, as well as up-and-comer efgartigimod for patients with the myasthenia gravis. diethyl (Z)-2-((2-cyano-2-(4-methoxyphenyl)vinyl)amino)malonate vendor & factory Grégoire brings more than 20 years of technological innovation, strategy and digital entrepreneurship experience to the team. He started his career as the founder and CEO of Andrexen, an innovative Unified Communication Cloud Platform. ,CHMP also recommended for approval Sanofi and Genzyme’s new Pompe disease drug, known in Europe as Nexviadyme (avalglucosidase alfa). Pompe disease is a rare, inherited disorder caused by the buildup of glycogen in the body’s cells.